Ampio Pharmaceuticals (AMPE) +18.1% premarket after announcing an agreement with India-based...

|About: Ampio Pharmaceuticals, Inc. (AMPE)|By:, SA News Editor

Ampio Pharmaceuticals (AMPE) +18.1% premarket after announcing an agreement with India-based Syngene to manufacture a combination product, Zertane-ED, to treat certain male sexual dysfunctions. The product will be used in Phase 3 trials in South Korea with AMPE partner Daewoong, which will finance and conduct the trials.